NCT00532220View on ClinicalTrials.gov

Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Osteonecrosis of the KneeBone Marrow Edema of the Knee
Interventions
DRUG

Ibandronate IV

Ibandronate IV (Bonviva® IV), 10.5 mg divided in 4 single infusions within 2 weeks(1x1.5 mg, 3x3 mg), followed by a fifth infusion after 3 months (V4)

DRUG

Placebo

Placebo IV, divided in 4 single infusions within 2 weeks, followed by a fifth infusion after 3 months (V4)

Trial Locations (1)

4031

University Hospital, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT00532220 - Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial | Biotech Hunter | Biotech Hunter